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Simple Summary: Due to their intrinsic aggressiveness, cancer stem cells (CSCs) represent an
essential target for the design of effective treatments against pancreatic cancer, one of the deadliest
tumors. As pancreatic CSCs are particularly dependent on the activity of their mitochondria, we
here focus on mitochondrial dynamics as a critical process in the homeostasis of these organelles.
We find that pancreatic CSCs rely on mitochondrial fission, and its pharmacological inhibition by
mDivi-1 resulted in the accumulation of dysfunctional mitochondria, provoking an energy crisis
and cell death in this subpopulation. Consequently, mDivi-1 blocked cellular functions related to
cancer aggressiveness such as in vivo tumorigenicity, invasiveness, and chemoresistance. Our data
suggest that the inhibition of mitochondrial fission represents a promising target for designing new
multimodal therapies to fight pancreatic cancer.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, partly due to
its intrinsic aggressiveness, metastatic potential, and chemoresistance of the contained cancer stem
cells (CSCs). Pancreatic CSCs strongly rely on mitochondrial metabolism to maintain their stemness,
therefore representing a putative target for their elimination. Since mitochondrial homeostasis de-
pends on the tightly controlled balance between fusion and fission processes, namely mitochondrial
dynamics, we aim to study this mechanism in the context of stemness. In human PDAC tissues, the
mitochondrial fission gene DNM1L (DRP1) was overexpressed and positively correlated with the
stemness signature. Moreover, we observe that primary human CSCs display smaller mitochondria
and a higher DRP1/MFN2 expression ratio, indicating the activation of the mitochondrial fission. In-
terestingly, treatment with the DRP1 inhibitor mDivi-1 induced dose-dependent apoptosis, especially
in CD133+ CSCs, due to the accumulation of dysfunctional mitochondria and the subsequent energy
crisis in this subpopulation. Mechanistically, mDivi-1 inhibited stemness-related features, such as
self-renewal, tumorigenicity, and invasiveness and chemosensitized the cells to the cytotoxic effects
of Gemcitabine. In summary, mitochondrial fission is an essential process for pancreatic CSCs and
represents an attractive target for designing novel multimodal treatments that will more efficiently
eliminate cells with high tumorigenic potential.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC), the most prevalent form of pancreatic can-
cer, is the third most frequent cause of cancer-related deaths nowadays [1]. Considering its
rising incidence, extreme aggressiveness, and the lack of effective treatments [2], pancreatic
cancer is predicted to become the second most frequent cause of deaths caused by cancer
by 2030 [3].
The main malignant features of PDAC, such as chemoresistance to conventional
systemic therapies, rapid relapse after treatment and metastasis formation in vital organs,
such as the liver and lungs, can be attributed to specific subpopulations of cancer cells
with tumor- and metastasis-initiating properties, known as pancreatic cancer stem cells
(CSCs) [4–7]. Although they represent a small fraction of the cancer cell population within
the tumor, CSCs are the main drivers of tumorigenesis in the pancreas and metastatic
sites, due to their self-renewal capacity and differentiation into rapidly proliferating cancer
cells. Additionally, their combined chemoresistance and tumorigenic capacity make them
responsible for disease relapse [4,6,8]. Therefore, identification of CSCs vulnerabilities is
essential in order to design more effective therapies against PDAC.
We recently discovered that pancreatic CSCs are particularly sensitive to mitochondrial
targeting, due to their extreme dependence on oxidative phosphorylation (OXPHOS) [9].
Essentially, pancreatic CSCs tightly control the expression balance between the glycolysis-
promoting oncogene c-MYC and the mitochondrial biogenesis transcription factor PGC1-
α, favoring mitochondrial metabolism in order to maintain full stemness. In fact, we
have demonstrated that perturbing mitochondrial function by either inhibition of the
electron transport chain (ETC) with the antidiabetic agent metformin [9,10] or altering
its redox state [9,11] significantly decreased pancreatic CSCs functionality and chemore-
sistance. Thus, our results identified mitochondrial activity as a key vulnerability for
pancreatic CSCs.
We have recently demonstrated that mitochondrial biogenesis driven by PGC1-α,
and recycling of dysfunctional mitochondria through ISGylation-mediated mitophagy are
essential processes for pancreatic CSCs [9,12]. In between these initial and final steps in
the lifecycle of mitochondria, fusion and fission represent the main events involved in
mitochondrial dynamics. Fusion and fission processes are controlled by different sets of
members of the Dynamin family, in conjunction with several adapter proteins. Specifically,
dynamin-related/-like protein 1 (DRP1), dynamin 2 (DNM2), mitochondrial fission 1
(FIS1), and mitochondrial fission factor (MFF) are involved in the fission process, where
one mitochondrion divides into two daughter mitochondria. On the other hand, mitofusins
1 and 2 (MFN1 and MFN2) and optic atrophy 1 (OPA1) control mitochondrial fusion, where
two mitochondria form one mitochondrion. The balance between these dynamic transitions
regulates size, number, distribution, and quality control of mitochondria, and therefore
are key to maintain their correct functionality [13]. Notably, mitochondrial dynamics are
essential for successful asymmetrical division in normal stem cells (SC) [14] and have
been linked to proliferation and survival of stem cells in normal tissues and some cancer
types [15,16].
Although increased mitochondrial fission has recently been linked to metabolic
changes induced by mutant KRAS in PDAC [17,18], our knowledge is still sparse concern-
ing the relationship between mitochondrial dynamics and stemness in this cancer type.
Here, we show that mitochondrial fission is particularly relevant for pancreatic CSCs, and
its inhibition with the compound mDivi-1 effectively diminishes CSC content in PDAC
patient-derived xenografts (PDXs). Indeed, mDivi-1 treatment resulted in the accumulation
of dysfunctional mitochondria that provoked energy crisis and apoptosis in CSCs. Finally,
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mDivi-1 inhibited stemness-related properties such as self-renewal, tumorigenicity, and
invasiveness and enhanced the toxicity of Gemcitabine, suggesting that inhibition of mito-
chondrial fission may represent an attractive target for the design of novel combinatory
therapeutic strategies for PDAC treatment.
2. Materials and Methods
2.1. Cell Culture and Patient-Derived Xenografts
PDAC patient-derived xenografts (PDAC PDX: 185, 215, 253 and 354) were obtained
through the Biobank of the Spanish National Cancer Research Centre (CNIO), Madrid,
Spain (references CNIO20-027, I409181220BSMH, 1204090835CHMH). Dissociation and
establishment of in vitro cultures were performed as previously described [19], and cells
were maintained for a maximum of 15 passages. PDXs were grown in RPMI (61870044)
supplemented with 10% FBS and 50 U/mL penicillin/streptomycin (all from Gibco, Life
Technologies, Carlsbad, CA, USA). For actual experiments, medium was switched to
DMEM/F12 (31331028) supplemented with 2% B27, 50 U/mL penicillin/streptomycin
(all from Gibco) and 20 ng/mL bFGF (Pan-Biotech, GmbH, Aidenbach, Germany). HPDE
(Human Pancreatic Duct Epithelial Cell Line) cells were grown in Keratinocyte Serum Free
Media supplemented with bovine pituitary extract and EGF (Gibco). HFF (Human foreskin
fibroblasts) were grown in DMEM supplemented with 10% FBS (61965026, Gibco). All the
cells were grown at 37 ◦C in a humidified 5% CO2 atmosphere.
2.2. Treatments
mDivi-1 was dissolved in DMSO following the manufacturer’s instructions (S7162,
Selleckchem, Munich, Germany). Depending on the experimental design, cells were
treated for 24 h to 7 days, at concentrations ranging from 10 to 80µM. DMSO compensation
was included in all the conditions to reach the DMSO concentration added in the higher
concentration used for each experiment (0.8% DMSO when the maximal concentration used
was 40 µM, 1.6% DMSO when the maximal concentration used was 80 µM). Gemcitabine
diluted in 0.9% sodium chloride (Eli Lilly, Indianapolis, IN, USA) was used as standard
chemotherapy with concentrations ranging from 1 nM to 5 µM. For experiments in hypoxia,
cells were maintained in 3% O2 in a ICO50med incubator (Memmert GmbH, Schwabach,
Germany).
2.3. Human Data Analysis
Expression data from human PDAC tissue and normal tissue were analyzed using
the webserver GEPIA2 (TCGA and the GTEx project databases; http://gepia2.cancer-pku.
cn/) accessed on 2 December 2019 [20] or OncomineTM (Badea, Buchholz, Grutzmann,
Iacobuzio-Donahue, Ishikawa, Logsdon, Pei, Segara databases). The Pearson correlation
coefficient was calculated to study the association of DNM1L gene with a stemness signa-
ture defined by the combined expression of the pluripotency-related genes NANOG, KLF4,
SOX2 and OCT4. For disease-free survival analysis, the Hazard Ratio (HR) was calculated
in GEPIA2 using the Cox Proportional Hazards model for pancreatic cancer patients from
the respective upper and lower quartiles of expression of the indicated genes.
2.4. Transmission Electron Microscopy (TEM)
PDAC 185 or 354 cells were used for TEM experiments. As described in [21], 185 cells
were sorted for CD133 expression and pellets were fixed with 0.1 M cacodylate buffer with
a pH of 7.4 at room temperature. Sections were processed by the USC Electron Microscopy
unit (Lugo, Galicia) per standard protocols. Pictures were taken with a JEM-1010 trans-
mission electron microscope (JEOL, Tokyo, Japan and analyzed by Adobe PhotoShop CS4
EXTENDED V11.0 (Adobe Systems, Montain View, CA, USA). 354 cells were seeded at
40,000 cells per compartment in 8-wells microscopy slides in 200µL of medium and treated
with mDivi-1 at 40 µM. After 48 h cells were fixed in glutaraldehyde (16210, Electron
Microscopy Science, Hatfield, UK) and samples processed by the Electron Microscopy
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of Biological Systems Unit at the University of Zaragoza following standard procedures.
Samples were visualized on a JEOL JEM 1010 100 kV microscope (JEOL, Tokyo, Japan).
Mitochondrial area quantification was performed using ImageJ.
2.5. Immunoblots
Treated cells were lysed in RIPA buffer (R0278, Sigma-Aldrich, St. Louis, MO, USA)
supplemented with protease inhibitors (J64156) and phosphatase inhibitors (J61022) (Alfa
Aesar, Thermo Fisher Scientific, Waltham, MA, USA). Proteins were quantified using the
Pierce™ BCA Protein Assay Kit (23225, Thermo Fisher Scientific). After the electrophoresis
process in 10% Tris-Glycine gels (XP001002, Invitrogen), proteins were transferred to a
PVDF membrane (88518, Thermo Fisher Scientific) and incubated overnight at +4 ◦C
with the different primary antibodies, listed below. After washes with PBS-Tween 0.1%,
the membranes were incubated with peroxidase-conjugated goat anti-rabbit or goat anti-
mouse secondary antibodies (656120 and A10685 respectively, Invitrogen). Bound antibody
complexes were detected using Pierce™ ECL Western Blotting Substrate (32109, Thermo
Fisher Scientific) and visualized on CL-X PosureTM Films (34091, Thermo Scientific). Bands
intensities were analyzed with ImageJ software and normalized to β-actin.
Antibodies against DRP1 (8570S, dilution 1:1000), MFN2 (11925S, dilution 1:1000),
LC3B (3868S, dilution 1:3000), P-AMPKα (2531S, dilution 1:1000), AMPKα (2532S, dilution
1:1000), were obtained from Cell Signaling Technology (Denvers, MA, USA). The OXPHOS
Human WB Antibody Cocktail (M5601-360, dilution 1:2000) was obtained from Abcam
(Cambridge, UK), and β-actin, clone AC-74 from Sigma Aldrich (A2228, dilution 1:10,000).
2.6. RNA Extraction and Quantitative Reverse Transcription Polymerase Chain
Reaction (RTqPCR)
Total RNA was extracted using TRIzol kit (Life Technologies) according to the man-
ufacturer’s instructions. Retrotranscription was performed with 1µg of total RNA using
SuperScript II reverse transcriptase (Life Technologies) and random hexamers. Quantitative
polymerase chain reaction (qPCR) was performed using PowerUp SYBR Green master
mix (Applied biosystems, Thermo Fisher Scientific), according to the manufacturer’s in-
structions. The primers used are detailed in Table 1. HPRT was used as endogenous
housekeeping control.
Table 1. List of primers used for real time PCR.














In total, 10,000 cells were seeded in triplicates in different 96-well plates and treated
24 h later in 200 µL of supplemented DMEM/F12 containing different concentrations of
mDivi-1 and/or Gemcitabine. After 3 and 7 days of treatment, cells were stained with
2% crystal violet (CV) (405831000, Acros Organics, Fisher Scientific) and dried. The CV
absorbance was assessed after dissolution in SDS (1% in PBS) at 590 nm. The proliferation
rate was normalized to control conditions, set to 100%.
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2.8. Cytotoxicity Assay
Cytotoxicity assays were performed using the MultiTox-Fluor Multiplex Cytotoxicity
Kit (G9201, Promega, Madison, WI, USA) following the manufacturer’s instructions.
2.9. Flow Cytometry Analysis and Sorting
After treatment, cells were trypsinized, washed once in PBS, and resuspended in
Blocking Buffer (2% FBS, 0.5% BSA in PBS) for 15 min on ice under agitation. Cells were
stained for 30 min at +4 ◦C with APC or PE-conjugated anti-CD133 antibodies (diluted
at 1/200 or 1/400 respectively; Biolegend, San Diego, USA) or corresponding control
Immunoglobulin G1 (IgG1, Biolegend) antibody as a control for non-specific staining.
After washes, pellets were resuspended in PBS with MitoTrackerTM Deep Red FM (MT)
(m22426, Life Technologies), MitoStatus TMRE (564696, BD Biosciences, San Jose, CA,
USA) or Cell ROX Deep Red reagent (1691766, Life Technologies) for 20 min at room
temperature. Annexin V-APC staining was performed on attached and floating cells
according to manufacturer’s instructions (550474 & 556454, BD Biosciences, San Diego, CA,
USA). Zombie Violet Dye (77477, Biolegend, San Diego, CA, USA) was used to exclude
non-viable cells. 50,000 cells per sample were analyzed using a FACS Canto II (BD, Franklin
Lakes, NJ, USA) and analyzed with FlowJo 9.2 software (Ashland, OR, USA). Moreover,
viable cells corresponding to the CD133 negative and positive populations were sorted
into 5 mL tubes containing full RPMI medium using a SONY SH800S instrument (SONY,
Tokyo, Japan).
2.10. XF Extracellular Flux Analyzer Experiments
In total, 30,000 cells per well were plated in XF96 Cell Culture Microplates (Sea-
horse Bioscience, Agilent, Santa Clara, CA, USA) previously coated with Cell-Tak (BD
Biosciences). For OCR determination, cells were incubated for 1 h in base assay medium
(D5030, Sigma Aldrich, Merck, Darmstadt, Germany) supplemented with 2 mM glutamine,
10 mM glucose, and 1 mM pyruvate, prior to OCR measurements using the XF Cell Mito
Stress Test Kit (Seahorse Bioscience). Concentrations for Oligomycin and FCCP were
adjusted for each primary cell type as follows: Oligomycin, 1.2 mM for 215 and 253; and
0.8 µM for 354 cells; FCCP 1.2 µM for 215 and 253; and 0.4 µM for 354 cells. Oligomycin,
FCCP, Rotenone and Antimycin A were dissolved in DMSO. For glycolytic metabolism
measurements, cells were incubated in basal media prior to injections using the XF Glyco
Stress Test kit (Seahorse Bioscience). For the evaluation of the acute response to mDivi-1,
different concentrations of mDivi-1 were injected in ports A–C, and the percentage of
complex I inhibition was calculated as the percentage of OCR inhibited upon mDivi-1
injection with respect to the inhibition obtained with Rotenone, the latter used as 100%, as
described previously [9]. Experiments were run in a XF96 analyzer (Seahorse Bioscience),
and raw data were normalized to protein content using the Pierce™ BCA Protein Assay
Kit (Thermo Fisher Scientific).
2.11. ATP Measurement
After treatment, cell pellets were washed with PBS and then resuspended in ultra-
pure water (10977035, Invitrogen). ATP was quantified using the ATP Determination Kit
(A22066, Invitrogen) following the manufacturer’s instructions. Normalization of data was
performed using protein concentrations measured on the same samples with the Pierce™
BCA Protein Assay Kit.
2.12. Sphere Formation Assay
Ten thousand cells were seeded, with or without treatment, in non-adherent plates
(ultra-low attachment plates (3473, Corning, NY, USA) or normal plates previously coated
with a 10% poly-2-hydroxyethylmathacrylate (polyHEMA, Sigma)), in 1 mL of supple-
mented DMEM/F12. After 7 days, formed spheres were counted using an inverted micro-
scope with 20× magnification.
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2.13. Colony Formation Assay
Either 500 or 1000 cells per well were seeded in 2 mL of supplemented DMEM/F12
with treatments. Media and treatments were refreshed every 7 days. After 21 days, cells
were stained with crystal violet and the number of colonies was manually counted.
2.14. Invasion Assay
Invasion assays were performed using 354 cells pretreated for 48 h with mDivi-1 40µM
in supplemented DMEM/F12 or conditioned media from M2-polarized macrophages
(MCM), previously demonstrated to induce EMT and stemness in our PDX models [22].
MCM was obtained as follows: leucocyte cones from anonymous healthy donors were
obtained from the National Blood Transfusion Service (UK) as approved by the City
and East London Research Ethics Committee (17/EE/0182). Cones were stored at 4 ◦C
and used within 24 h of delivery to maintain cell viability. Monocyte-derived human
macrophage culture, polarization into M2-like macrophages and generation of conditioned
medium were performed as previously described [22]. In brief, monocyte-derived human
macrophage cultures were maintained in IMDM (Gibco), supplemented with 10% human
AB serum, and polarized by incubation with 0.5 ng/mL of macrophage colony-stimulating
factor for 48 h (MCSF; PeproTech, Rocky Hill, NJ, USA). To obtain conditioned media,
macrophages were washed with PBS and cultured for additional 48 h in supplemented
DMEM:F12 (see Section 2.1). Media was then collected, centrifuged, and the supernatant
stored at −80 ◦C.
After treatments, cells were trypsinized and counted, and 150,000 cells were seeded
on top of 8.0 µm PET membrane invasion chambers coated with growth factor reduced
Matrigel (354480, Corning, NY, USA) in serum free media. After 24 h, the invasion of cells
towards 20% FBS was assessed after fixation with 4% formaldehyde and staining with
crystal violet. Five fields per well were manually counted at 20× magnification.
2.15. Wound Healing Assay
For the wound healing assay, 50,000 cells per well were seeded in ImageLock 96 w
plates (IncuCyte® technology). Once the cells were confluent, scratches were performed
and, after washing with PBS, cells were incubated in supplemented DMEM/F12 or MCM
media with or without different concentrations of mDivi-1. Cell migration was moni-
tored using IncuCyte® Live-Cell Analysis System (Sartorius, Göttingen, Germany). The
percentage of wound closure was calculated using the IncuCyte® Software.
2.16. In vivo Extreme Limiting Dilution Assay (ELDA)
In total, 354 cells were treated with 40 µM of mDivi-1 for 72 h, trypsinized and
resuspended in supplemented DMEM/F12 with Matrigel (50:50). Two doses of cells
(1000 or 10,000 cells), were subcutaneously injected in both flanks of 6 weeks-old nude
(Foxn1nu) male and female mice (n = 6 mice per group). Tumor size was measured using
a caliper and followed for 10 weeks, when the control tumors had reached the humane
endpoint. The ELDA calculation was performed at http://bioinf.wehi.edu.au/software/
elda/ accessed on 28 January 2020. Mice were housed according to institutional guidelines
and all experimental procedures were performed in compliance with the institutional
guidelines for the welfare of experimental animals as approved by the Universidad of
Zaragoza Ethics Committee (CEICA PI22/17) and in accordance with the guidelines for
Ethical Conduct in the Care and Use of Animals as stated in The International Guiding
Principles for Biomedical Research involving Animals, developed by the Council for
International Organizations of Medical Sciences (CIOMS).
2.17. Statistical Analysis
Data are presented as the mean ± S.E.M. A Mann–Whitney test or Student’s t-test
were used for two group comparisons and a Kruskal–Wallis test or one-way analysis of
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variance (ANOVA) for multiple comparisons. Data were analyzed using GraphPad Prism
and differences were considered significant at p < 0.05.
3. Results
3.1. Mitochondrial Fission Is Associated with Stemness and Epithelial-to-Mesenchymal Transition
in Human PDAC
Firstly, a bioinformatic analysis using the webserver GEPIA2 was performed to de-
termine the relative expression of the main genes regulating mitochondrial dynamics in
transcriptional data from normal human pancreas and PDAC tissues included in the TCGA
and GTEx projects (DNM1L, DNM2, FIS1, and MFF for fission; MFN1, MFN2, and OPA1 for
fusion) (Figure 1A). Except for MFF and MFN1, all other genes involved in mitochondrial
dynamics showed a statistically significant upregulation in PDAC tumoral tissue com-
pared to normal tissue. Differences remained significant when the genes were combined
together as a mitochondrial dynamics signature. Interestingly, PDAC patients expressing
this signature had a lower survival (Figure S1A).
Next, we interrogated eight additional PDAC datasets to study the expression of
these genes in tumor vs. normal tissue. Although the results varied across datasets,
DNM1L and MFF, both related to mitochondrial fission, were consistently and significantly
overexpressed in PDAC tissue (Figure 1B). These results support the implication of the
mitochondrial fission process in PDAC and are in line with recent studies demonstrat-
ing a crucial role of mitochondrial fission in metabolic changes related to mutant KRAS
in PDAC [17,18]. Notably, DNM1L expression strongly correlated with gene signatures
associated with aggressiveness in PDAC: the stemness signature routinely used by our
group (NANOG, OCT4, KLF4, SOX2; Figure S1B) and the epithelial-to-mesenchymal transi-
tion (EMT) signature formed by ZEB1, SNAI1, and SNAI2 (Figure S1C). Indeed, the joint
overexpression of DNM1L and the above stemness signature predicted a decreased overall
survival in PDAC patients (Figure S1D). Overall, these results suggested an association of
mitochondrial fission and signatures related to pancreatic CSCs and aggressiveness.
We next aimed to further validate the putative relationship between mitochondrial
dynamics and stemness using four different PDX-derived primary cultures. We selected
DRP1 (encoded by DNM1L) and MFN2 as representative proteins for mitochondrial fis-
sion or fusion, respectively. As shown in Figure 1C, the DRP1/MFN2 expression ratio
was increased in CSC-enriched conditions (cells grown as spheres or CD133+ sorted cells)
compared to their differentiated counterparts (cells grown in adherence or CD133− sorted
cells), suggesting a strong activation of the mitochondrial fission process in CSCs. As we
have previously demonstrated [9], the total mitochondrial mass as determined by flow
cytometry was higher in CD133+ cells compared to CD133− cells (Figure 1D). However, the
combined mitochondrial area as assessed by transmission electron microscopy (TEM) was
significantly lower in CD133+ cells compared to CD133− cells, in line with increased mito-
chondrial fission activity in pancreatic CSCs (Figure 1E and Figure S1F). Consistent results
were observed for cells treated with conditioned media from M2-polarized macrophages
(macrophage conditioned media, MCM), previously demonstrated to induce EMT and
stemness in our PDX-derived models [22,23] (Figure S1E). Together, our results demon-
strate that the enhanced mitochondrial fission process in PDAC is mostly confined to the
CSC compartment.
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Figure 1. Mitochondrial fission is associated with stemness in human pancreatic ductal adenocarcinoma (PDAC). (A,B) 
Relative expression of genes regulating mitochondrial dynamics for normal human pancreas (N) and PDAC tissues (T), 
respectively, using TCGA and GTEx ((A) webtool GEPIA2) or other datasets ((B) OncomineTM). TPM, transcripts per mil-
lion. *p < 0.01. In (B), the color-coded rank illustrates the rank of the p-value for each indicated gene relative to the global 
list of up-regulated genes for the respective dataset (top 1%, top 10%). (C) Western blot for DRP1 and MFN2 in cancer 
stem cell (CSC)-enriched conditions (spheres (Sph) or CD133+ sorted cells) compared to their differentiated counterparts 
(cells grown in adherence (Adh) or CD133− sorted cells) in four different PDAC models. The numbers below show the 
normalized DRP1/MFN2 expression ratio. β-actin was used as a loading control. (D) Mitochondrial mass as determined 
by flow cytometry using MitoTrackerTM Deep Red FM (Mito DR) in CD133− and CD133+ cells (n = 6–8). Control set as 1 for 
fold change. (E) Transmission Electron Microscopy pictures (12,000×) and quantification of the mitochondrial area for 
Figure 1. Mitochondrial fission is associated with stemness in human pancreatic ductal adenocarcinoma (PDAC). (A,B)
Relative expression of genes regulating mitochondrial dyna ics for normal human pancreas (N) and PDAC tissues (T),
respectively, using TCGA and GTEx (( tool GEPIA2) or other datasets ((B) OncomineTM). TPM, transcripts per
million. * p < 0.01. In (B), the color-coded rank illustrates the rank of the p-value for each indicated gene relative to the
global list of up-regulated genes for the respective dataset (top 1%, top 10%). (C) Western blot for DRP1 and MFN2 in cancer
stem cell (CSC)-enriched conditions (spheres (Sph) or CD133+ sorted cells) compared to their differentiated counterparts
(cells grown in adherence (Adh) or CD133− sorted cells) in four different PDAC models. The nu bers below show the
normalized DRP1/MFN2 expression ratio. β-actin was used as a loading control. (D) Mitochondrial mass as determined
by flow cytometry using MitoTrackerTM Deep Red FM (Mito DR) in CD133− and CD133+ cells (n = 6–8). Control set
as 1 for fold change. (E) Transmission Electron Microscopy pictures (12,000×) and quantification of the mitochondrial
area for CD133− and CD133+ 185 cells, respectively (n = 7–17 cells or 54 vs. 107 mitochondria). ** p < 0.01, *** p < 0.001,
**** p < 0.0001; Mann–Whitney test. Data represent averages ± S.E.M.
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3.2. The DRP1 Inhibitor mDivi-1 Induces Apoptosis in Primary Pancreatic Cancer Cells,
Especially Affecting the CD133+ Subpopulation
Considering our results, we aimed to inhibit the mitochondrial fission process with
the selective inhibitor of DRP1 mDivi-1 as a novel approach to target pancreatic CSCs,
representing cells with enhanced tumorigenic and invasive potential. Using four PDX-
derived models, the EC50 for mDivi-1 on PDAC proliferation was >32 µM for three days
of treatment and ranged from 18 to 55 µM for seven days of treatment (Figure S2A,B).
Expectedly, cells became more resistant to the drug when cultured in hypoxia, as they
switch to a non-mitochondrial oxygen-independent metabolism (Figure S2C). Therefore,
subsequent experiments were performed using mDivi-1 concentrations between 10 and
80 µM.
Next, using the indicated doses of mDivi-1, a series of cytotoxicity assays were per-
formed on two different PDX-derived cultures and two non-tumoral cell lines (i.e., normal
pancreatic ductal epithelial cells (HPDE) and human foreskin fibroblasts (HFF)) (Figure 2A).
Interestingly, only PDAC cells were sensitive to the drug, even at the highest doses, suggest-
ing that maintenance of a high rate of mitochondrial fission is only critical for PDAC cells.
Interestingly, 72 h of treatment with mDivi-1 induced a significant and dose-dependent
increase in cell death in PDX-derived cells (Figure 2B), which was particularly evident for
CD133+ cells (Figure 2C). Indeed, CD133+ cells were significantly more sensitive to mDivi-1
than CD133– cells, with 70% cell death for 80 µM of mDivi-1 in CD133+ compared to 40%
for CD133– cells (Figure 2C), therefore resulting in a marked decrease of the CD133+ CSC
content (Figure 2D,E). In summary, our results suggest that the inhibition of mitochondrial
fission is toxic for PDAC cells, particularly for the CD133+ subpopulation.
3.3. mDivi-1 Treatment Disrupts Mitochondrial Function
In order to understand why the inhibition of mitochondrial fission was particularly
toxic for pancreatic CSCs, we studied the effects of mDivi-1 treatment on mitochondrial
metabolism, a well-known vulnerability of these cells, which we have previously de-
scribed [9]. As an expected direct consequence of blocking mitochondrial fission, mDivi-1
treatment significantly increased the mitochondrial size compared to the control condi-
tion (Figure 3A). This effect was accompanied by an increase in mitochondrial mass per
cell (Figure S3A), which was statistically significant for CD133+ cells only (Figure S3B).
However, we could not detect a significant increase in the expression of mitochondrial
respiratory chain complexes as assessed by Western blot (Figure S3C). Importantly, many
mitochondria exhibited a disorganized internal structure following mDivi-1 treatment
(Figure 3B), suggesting a likely accumulation of damaged or unhealthy mitochondria.
Accordingly, mitochondrial activity as assessed by the probe TMRE cells was dis-
turbed, although no clear diminishing pattern could be observed for the bulk cancer cell
population (Figure 3C). Still, mDivi-1 treatment was accompanied with doubled Reactive
Oxygen Species (ROS) production in bulk cancer cells (Figure 3E). Notably, when studying
the effect of mDivi-1 on subpopulations of cancer cells, we found that the mitochondrial
membrane potential remained mostly unchanged in CD133– cells, whereas a significant
drop could be noted exclusively for CD133+ cells (Figure 3D). This diminished mitochon-
drial functionality in CD133+ cells resulted in even more pronounced ROS accumulation
(Figure 3F). Since CSCs are particularly sensitive to inhibition of mitochondrial function
and oxidative damage [9,11], these treatment effects of mDivi-1 could, at least in part, ex-
plain its marked toxicity in CSCs. Notably, mDivi-1 treatment also increased the expression
of LC3B (Figure S3D), which suggests the activation of autophagy as a counteractive mech-
anism to avoid the excessive accumulation of defective mitochondria; however, as we have
previously shown [12], activation of autophagy does not necessarily ensure mitophagy,
especially not when fission is inhibited.
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Figure 2. mDivi-1 treatment targets PDAC cancer cells and induces apoptosis in CSCs. (A) Cytotoxicity assay in response 
to mDivi-1 treatment for 72 h using 215 and 253 PDAC cells, non-transformed human pancreatic ductal epithelial cells 
(HPDE), and human foreskin fibroblasts (HFF). (B,C) Total cell death for different PDAC models after 72 h of mDivi-1 
treatment, calculated for the entire cancer cell population (B) or for CD133− and CD133+ cells (C) after staining for Annexin 
V-APC and Zombie Violet. (D) CD133 content in response to mDivi-1 treatment for 72 h, as evaluated by flow cytometric 
Figure 2. mDivi-1 treatment targets PDAC cancer cells and induces apoptosis in CSCs. (A) Cytotoxicity assay in response
to mDivi-1 treatment for 72 h using 215 and 253 PDAC cells, non-transformed human pancreatic ductal epithelial cells
(HPDE), and human foreskin fibroblasts (HFF). (B,C) Total cell death for different PDAC models after 72 h of mDivi-1
treatment, calculated for the en ire cancer cell population (B) or for CD133− and CD133+ cells (C) after staining for Annexin
V-APC and Zombie Violet. (D) CD133 content in response to mDivi-1 treatment for 72 h, as evaluated by flow cytometric
analysis in three different PDAC models. (E) Representative experiment in 253 cells from (D) * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001 vs. Control; ## p < 0.01, ### p < 0.001 vs. CD133− cells; ANOVA with Bonferroni’s post-test (A–C)
or Kruskal–Wallis with Dunn’s post-test (D) Data represent averages ± S.E.M. Control is set as 1 for fold change.
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treated cells as shown in (A), demonstrating altered mitochondrial morphology. (C,D) Ratio of mitochondrial activity as 
assessed by TMRE on mitochondrial mass (Mito DR) for bulk cancer cells (C) or for CD133– vs. CD133+ cells. Pooled data 
for 215, 253, and 354 PDAC cells (D) (n = 4–9). (E,F) Reactive Oxygen Species (ROS) production as assessed by DCFDA for 
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The intricate balance between the mitochondrial biogenesis factor PGC-1α and c-
MYC, jointly controlling the metabolic phenotype and stemness of PDAC cells [9], was
altered upon mDivi-1 treatment. The balance had shifted towards a more glycolytic
phenotype with increased MYC expression and subsequently decreased expression of
PGC1A (Figure 4A), most likely to compensate for the deleterious effects of accumulating
defective mitochondria. Therefore, we next studied the effects of mDivi-1 on the oxygen
consumption rate (OCR). Indeed, mDivi-1 treatment dose-dependently decreased both
basal oxygen consumption and maximal respiration (Figure 4B), as well as ATP-linked
OCR at the highest doses (Figure 4C). Importantly, acute injection of mDivi-1 did not
result in a consistent inhibition of OCR consumption (Figure S4A), arguing against a
possible unspecific inhibition of the mitochondrial respiration as previously suggested [24].
Importantly, the observed drop in ATP-linked respiration translated into a significant
drop in ATP content for CSC-enriched cultures only (spheres, Figure 4D). Notably, these
cells were not capable of consistently increasing glycolysis (differences significant only
for 253 cells at 10 and 80 µM, respectively) in order to compensate for the loss of ATP
production upon mitochondrial inhibition (Figure S4B–D), even though MYC expression
had increased (Figure 4A). Consistently, this ATP drop in CSC-enriched cultures led to the
activation of the AMP-activated protein kinase (AMPK), the main sensor of cellular energy
homeostasis, indicative of energy stress (Figure 4E). Of note, the observed increase in the
phospho-AMPK/AMPK ratio was mainly due to the downregulation of total AMPK upon
mDivi-1 treatment.
Overall, our results demonstrate that dysregulation of mitochondrial dynamics in
response to mDivi-1 treatment led to the accumulation of defective mitochondria in PDAC
cells, which translated specifically into an energy crisis in the CSC compartment.
3.4. mDivi-1 Treatment Blocks CSC Functionality
Since we demonstrated that treatment with mDivi-1 was particularly toxic for CSCs
due to their metabolic peculiarities, we next performed diverse functional assays to analyze
the different features associated with stemness and aggressiveness in response to mDivi-1
treatment.
We first checked the expression of stemness-related genes after treatment with mDivi-
1, which revealed that SOX2 downregulation was the only common event when comparing
two different PDX models (Figure 5A). Next, we studied the self-renewal capacity of PDAC
cells in response to mDivi-1 using sphere and colony formation assays. mDivi-1 treatment
dose-dependently reduced the number of formed spheres by >50% compared to the control
condition (Figure 5B). Furthermore, mDivi-1 essentially inhibited the ability of treated cells
to form colonies at the highest dose tested (Figure 5C).
Finally, to explore the effect of mDivi-1 on tumorigenicity and CSC content, we
performed in vivo extreme limiting dilution assays (ELDA) (Figure 5D). Two doses of cells
(103 or 104 cells) pre-treated for three days with 40 µM of mDivi-1 were subcutaneously
injected into immunocompromised mice and tumor formation was followed for 10 weeks.
Interestingly, cells pre-treated with mDivi-1 only formed a single small tumor in each group
and, as such, the estimated content of CSCs decreased more than 10-fold (from 1/1425 to
1/20,041 cells; p < 0.001) (Figure 5D). Overall, these results demonstrated that the inhibition
of mitochondrial fission via mDivi-1 treatment functionally impaired in vitro self-renewal
and in vivo tumorigenicity.
We next tested mDivi-1 treatment effects on CSC properties that define the aggressive-
ness of PDAC, e.g., invasiveness and chemoresistance. PDAC cell migration and invasion
was induced by MCM, which were considerably inhibited by mDivi-1 treatment at 40 µM
(Figure 6A,B). Interestingly, mDivi-1 did not reverse the MCM-induced upregulation of
EMT genes (Figure 6C), suggesting that inhibition of mitochondrial fission does not in-
terfere with the EMT genetic program per se, but rather impedes downstream cellular
functions.
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Figure 5. mDivi-1 treatment inhibits self-renewal and in vivo tumorigenicity. (A) Relative pluripotency genes expression
in 215 and 354 cells treated with 40 µM mDivi-1 for 72 h (n = 5–7). (B) Number of spheres formed after seven days with
or without mDivi-1 treatment (n = 2–6). (C) Colony formation during 21 days with or without mDivi-1. Upper panel,
quantification. Lower panel, representative images for 253 cells (n = 3–6). (D) In vivo extreme limiting dilution assay
(ELDA). Subcutaneous injection of 103 or 104 354 cells pretreated for 72 h with 40 µM of mDivi-1. Left, images of the tumors
obtained after 10 weeks. Right, percentage of tumorigenicity over time for each group, allowing for CSC frequency (1 CSC/x
total cancer cells) estimation (n = 6 tumors per group). Data shown in the figure represent averages ± S.E.M. * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001; Kruskal–Wallis with Dunn’s post-test. Controls set as 1 or 100% for fold changes.
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assay in Boyden’s chamber of MCM-treated 354 cells after treatment with mDivi-1 40 µM. (n = 6). Top, representative 
images of crystal violet stained cells after 24 h of migration. Bottom, quantification. (C) Relative EMT gene expression 
(pooled data of 215 and 354 cells, n = 4). (D) Evaluation of the proliferation rate of the indicated PDX cultures after seven 
days of treatment with Gemcitabine (nM) with or without 40 µM mDivi-1 (n = 3–7). (E) Sphere formation ability in the 
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Finally, considering the essential role of mitochondria in chemoresistance across
different cancer types [25] and the intrinsic chemoresistance of CSCs, we studied the
response to Gemcitabine treatment in the context of mitochondrial fission inhibition. First,
mDivi-1 treatment synergized with Gemcitabine for inhibiting cell proliferation (Figure 6D),
an effect especially noticeable in 215 cells which were totally resistant to Gemcitabine alone.
Even more importantly, we observed a summatory effect for the two drugs on the ability
of the cells to form spheres (Figure 6E). In general, the addition of mDivi-1 improved the
response to Gemcitabine alone, suggesting that this combined treatment strategy could be
more efficient in targeting chemoresistant cells.
In summary, our results demonstrate that the inhibition of mitochondrial fission
efficiently targets pancreatic CSCs with pronounced aggressive features, such as enhanced
tumorigenicity, invasiveness, and chemoresistance, through the accumulation of defective
mitochondria and subsequent energy crisis leading to loss of stemness and cell death.
4. Discussion
Emerging evidence indicates that mitochondrial fission, and particularly DRP1, are
involved in the pluripotency and functionality of SCs [14,15,26]. For instance, genetic
modulation of DNML1 expression or DRP1 activity modified the differentiation state of
embryonic SCs or reprogrammed fibroblasts, pushing cells into differentiation or pluripo-
tency, respectively [26,27]. In line with previous reports, our present data now demonstrate
a similarly close relationship between DRP1 and stemness for pancreatic cancer. CSCs from
glioblastoma were shown to depend on DRP1 activity for growth and self-renewal and,
importantly, DRP1 phosphorylation correlated with patient survival [28]. Similarly, we
found a positive correlation between DNM1L expression and stemness-related signatures in
human PDAC samples, resulting in a novel stemness signature that is capable of predicting
patients’ outcome (Figure S1). Importantly, we further corroborated these expression data
using our PDAC models and demonstrated that pancreatic CSCs accumulate significantly
smaller mitochondria, correlating with an increased DRP1/MFN2 ratio, both indicative of
increased mitochondrial fission activity (Figure 1C–E).
It is well accepted that elevated fission activity results in mitochondrial fragmentation
and impaired OXPHOS, whereas increased fusion activity leads to enhanced oxidative
metabolism [29]. However, as opposed to normal SCs featuring glycolytic metabolism, we
have previously demonstrated that pancreatic CSCs are fundamentally oxidative, despite
their increased mitochondrial fission activity [9]. In fact, there are countless examples
of glycolytic cells showing fragmented mitochondria, a phenomenon which is regulated
by KRAS-dependent DRP1 activation in the case of PDAC tumors [17,18]. Moreover, it
has been shown that overexpression of an activating DRP1 mutant enhanced glucose
uptake and lactate release in leukemia cells [30]. Interestingly, this discrepancy between
the mitochondrial architecture and the cellular metabolic phenotype can also be observed
in the context of stemness in embryonic and neuronal SCs, which show fragmented and
fused mitochondria, respectively, linked to glycolytic metabolism [26,31].
This apparent controversy might be solved considering that mitochondrial fusion or
fission may not represent merely static metabolic phenotypes, but rather dynamic pro-
cesses that modulate energy expenditure in response to metabolic demands. This suggests
that environmental factors and culture conditions have a strong impact on mitochondrial
architecture. For instance, pancreatic beta-cells exposed to nutrient excess or physiologic un-
couplers of mitochondria show increased respiration combined with fragmentation of their
mitochondrial networks [32]. In these conditions, cells enhance nutrient oxidation at maxi-
mal respiratory rate while mitochondrial fission favors uncoupled respiration (decreased
ATP synthesis efficiency) in order to avoid ROS overproduction and prevent oxidative
damage [33]. Since we have described that sustaining low mitochondrial ROS content is
essential for maintaining self-renewal and full functionality of pancreatic CSCs [9,11], we
hypothesize that a similar mechanism might be operative in oxidative pancreatic CSCs
to prevent excessive ROS accumulation due to elevated proton leak as compared to their
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differentiated counterparts (unpublished data). Despite this apparent similarity between
beta-cells and CSCs, metabolism of pancreatic beta-cells is clearly distinct and adapted
to the regulation of insulin secretion: on the one hand, glucose sensing is controlled by
supply-driven oxidative metabolism [34]; on the other hand, beta-cells downregulate an-
tioxidant defenses to facilitate intracellular redox signaling, which is essential for insulin
secretion [35].
Consistently, the toxic effects observed with mDivi-1 in CSCs show a strong compo-
nent of energetic crisis derived from the loss of mitochondrial function. Treatment with
mDivi-1 in our model systems induced the accumulation of dysfunctional mitochondria
with two major consequences: (1) ROS accumulation (Figure 3E), which is particularly
deleterious for CSCs; and (2) diminished mitochondrial respiration, which translated
into lower ATP content specifically in CSC-enriched cultures (Figure 4B–E). Importantly,
DRP1 genetic loss in PDAC impaired tumor growth and showed analogous features in
terms of mitochondrial dysfunction [17], validating our experimental approach using the
pharmacological inhibitor mDivi-1. As we have previously reported for the inhibition of
mitochondrial activity by metformin [9,10], ROS accumulation and inhibition of respira-
tion have different consequences for PDAC cells depending on their differentiation state:
proliferation blockade in bulk tumor cells, and energy crisis and cell death in CSCs, as most
PDAC CSCs are unable to switch to glycolysis in order to maintain their energy levels and
their increased sensitivity to oxidative stress (Figure S4) [9,11]. Importantly, other studies
also described loss of mitochondrial respiration and cell death in brain and breast CSCs
upon mDivi-1 treatment [28,36], suggesting that DRP1-mediated fission supports stemness
in different tumor types.
One of the major consequences of DRP1 loss in PDAC is the accumulation of dysfunc-
tional mitochondria subsequent to the blockade of mitophagy, leading to tumor growth
inhibition [17]. Indeed, apart from restraining ROS production and oxidative damage
by promoting uncoupled respiration, we can hypothesize that maintaining mitochondria
in a fragmented state supports mitochondrial fitness by facilitating a rapid replacement
of unhealthy/damaged mitochondria in CSCs. In fact, our results indicate that the accu-
mulation of defective mitochondria is most pronounced in CD133+ cells (Figure 3D and
Figure S3B), as compared to their differentiated CD133− counterparts. Most likely, this
reflects their accelerated mitochondrial biogenesis [9] and mitophagy [12] rates that are
required for their elevated oxidative metabolism, prone to induce oxidative damage of
mitochondria. Indeed, we have demonstrated that interfering with the various stages of
the mitochondrial lifecycle from biogenesis to mitophagy, including fission and fusion
processes, will severely impact pancreatic CSC functionality. Reducing mitochondrial
biogenesis by PGC-1α knockdown or MYC overexpression [9], interfering with mitophagy
by blocking mitochondrial ISGylation via genome editing [12], or inhibiting mitochondrial
fission with mDivi-1 did not only affect mitochondrial activity, but also impaired self-
renewal and in vivo tumorigenicity (Figure 5). In fact, although there are still large gaps
in our understanding of the interplay between mitochondrial dynamics, cell metabolism,
and stemness in cancer, it is increasingly appreciated that tightly controlled mitochondrial
homeostasis is essential for pancreatic CSCs functionality.
Indeed, here we provide proof-of-concept for the essential role of mitochondrial fis-
sion in PDAC stemness. Pharmacological inhibition of mitochondrial fission by mDivi-1
induced cell death in PDAC cells, with particular toxicity in the CD133+ subpopulation
(Figure 2B–E). This decrease in the percentage of CSCs translated into diminished sphere
and colony formation in vitro and tumorigenicity in vivo (Figure 5). Similar results have
been described in brain and breast cancer, where mDivi-1 selectively killed the CSC sub-
population, resulting in diminished stemness and delayed tumor growth [28,36].
Importantly, inhibition of mitochondrial fission does not only decrease self-renewal
and tumorigenicity, but also directly impacts the migratory and invasive abilities of PDAC
cells (Figure 6A,B). Indeed, the promotion of invasiveness associated with mitochondrial
fragmentation was already reported for other cancer types such as oncocytic thyroid
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carcinomas [37] as well as breast and lung cancers [38], where forced mitochondrial fusion
inhibited colony formation, tumorigenicity and invasiveness. Indeed, invasive breast
carcinomas and metastases express higher levels of DRP1 and lower levels of MFN1
compared to non-metastatic breast tumors [39]. Interestingly, and supported by our data,
this effect is not transcriptional but rather functional: it has been proposed that fission
maintains the required mitochondrial ATP synthesis activity to support the high energetic
cost of F-actin polymerization, essential for lamellipodia formation [39].
Linking the intrinsic chemoresistance of CSCs to mitochondrial function is another
emerging theme [25]. Interestingly, several previous works connect mitochondrial dynam-
ics with chemoresistance in different cancer types [40–42]. In PDAC, we have shown that
treatment with mDivi-1 sensitized PDAC cells to Gemcitabine treatment (Figure 6D,E).
Importantly, although much more pronounced in the context of self-renewal (Figure 6E),
this effect was not restricted to CSCs, since we could observe a more pronounced inhibition
of proliferation by mDivi-1 and Gemcitabine treatment in the entire population of tumor
cells (Figure 6D). These results suggest that the inhibition of mitochondrial fission may
not only diminish the probability for disease relapse by eliminating CSCs, but may also
slow down tumor progression. Consistently, mDivi-1 has also been shown to sensitize
breast and ovarian cancer cells to cisplatin [41,42]. Although our data and these reports
would suggest a role for mitochondrial fission in chemoresistance, studies in gynecological
cancers have shown that maintaining the mitochondria in a fusion state contributes to
chemoresistance, which was reversed by enforced fission [40].
Importantly, mDivi-1 treatment had no demonstratable impact on non-transformed
cells (Figure 2A), in line with previous studies, and therefore suggesting a yet unchartered
therapeutic opportunity for cancer [35]. While these data indicate a favorable therapeutic
window for the inhibition of mitochondrial fission, for now the use of mDivi-1 should
only be considered as proof-of-concept. First, the pharmacological specificity of mDivi-1
is still under debate [24,43,44] as Bordt et al. suggested that its effect on mitochondrial
fission is related to mitochondrial complex I inhibition [24]. However, several findings
in our study do support the specificity of mDivi-1 as mitochondrial fission inhibitor. The
accumulation of dysfunctional mitochondria and enhanced ROS production (Figure 3B–F)
reproduce the outcome of genetic targeting of DRP1 in PDAC [17]. In fact, accumulation of
enlarged mitochondria (Figure 3A) can only be explained as a result of mitochondrial fission
inhibition. Moreover, we evaluated the percentage of complex I inhibition in response
to different concentrations of mDivi-1 and it mostly remained below 10% (Figure S4A).
Finally, while mDivi-1 has been used successfully in mice [28], its in vivo use is limited
by poor lipophilicity, solubility, and pharmacodynamics [18,43]. These features would
need to be improved before such a compound could be considered for further translational
studies. However the lack of toxicity for non-transformed cells, its inhibitory effects on
cancer cell growth, the chemosensitization, and the preferred elimination of CSCs represent
convincing evidence for further advancing this concept into the clinic. Our study and
previous works jointly demonstrate the suitability of mitochondrial fission inhibition as a
promising strategy for developing more effective treatments for PDAC patients.
5. Conclusions
The process of mitochondrial fission is especially active in pancreatic CSCs, represent-
ing a novel and attractive therapeutic vulnerability for the elimination of this aggressive
subpopulation of cancer cells. Pharmacological inhibition of mitochondrial fission induces
accumulation of dysfunctional mitochondria, which is particularly lethal for CSCs, due to
their restricted ability to activate alternative pathways for energy production. Multimodal
treatments combining the inhibition of mitochondrial fission and chemotherapy could be
useful to combat the still miserable survival rates of PDAC patients.
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